REMARKS/ARGUMENTS

The Office has required restriction in the above-listed application as follows:

Group I: Claims 1-7, 18, 19 and 22, drawn to a peptide, or a cancer vaccine or pharmaceutical composition comprising said peptide, said peptide being a distinct peptide selected from the group consisting of SEQ ID NOS: 2-6 and 66-68. In addition, Applicant is to select one distinct peptide sequence as the invention.

Group II: Claims 13 and 18, drawn to an antibody to peptide, or cancer vaccine or pharmaceutical composition consisting of a peptide of SEQ ID NOS: 2-6 and 66-68. Applicants is to select one distinct antibody as the invention.

Group III: Claims 8-11, 22, 26-28, and 31, drawn to a polynucleotide encoding a peptide selected from the group consisting of SEQ ID NOS: 2-6 and 66-68; or a vector or cell expressing a vector comprising said polynucleotide. Applicant is to select on distinct polynucleotide as the invention.

Group IV: Claims 14-15, 19, 22, 29 and 32, drawn to a cell presenting antigens to a peptide an antibody to a peptide, or cancer vaccine or pharmaceutical composition consisting of a peptide selected from the group consisting of SEQ ID NOS: 2-6 and 66-68. Applicant is to select one distinct cell presenting antigen as the invention.

Group V: Claims 16-17, 22 and 30, drawn to a cytotoxic T-lymphocyte (CTL) comprising a complex between HLA-A24 antigen to a peptide selected from the group consisting of SEQ ID NOS: 2-6 and 66-68. Applicant is to select one distinct CTL complex as the invention.

Group VI: Claim 12, drawn to a method of making a peptide selected from the group consisting of SEQ ID NOS: 2-66 and 66-68. Applicant is to select one distinct peptide as the invention.

Group VII: Claim 21 and 25, drawn to a method for treatment or prevention of cancer with a peptide of SEQ ID NO: 7 or a peptide selected from the group consisting of SEQ ID NOS: 2-6 and 66-68. Applicant is to select one distinct peptide as the invention.

Group VIII: Claims 25 and 33-34, drawn to a method for treatment or prevention of cancer using a polynucleotide encoding a peptide of SEQ ID NOS: 7 or a peptide selected from the group consisting of SEQ ID NOS: 2-6 and 66-68; or a vector or cell expressing a vector comprising said polynucleotide. Applicant is to select one distinct peptide as the invention.

Group IX: Claims 25 and 35, drawn to a method for treatment or prevention of cancer using an antigen presenting cell, peptide of SEQ ID NO: 7 or a peptide selected from the group consisting of SEQ ID NOS: 2-6 and 66-68 complexed to an HLA-A24 antigen. Applicant is to select one distinct peptide as the invention.

Group X: Claims 25 and 33, drawn to a method for treatment or prevention of cancer with a cytotoxic T-lymphocyte (CTL) comprising a complex between an HLA-A24 antigen to a peptide of SEQ ID NO: 7 or a peptide selected from the group consisting of SEQ ID NOS: 2-6 and 66-68. Applicant is to select one distinct CTL complex as the invention.

Applicants have elected, Group I: Claims 1-6, 18-19, and 22, for further prosecution. Additionally, Applicants elect SEQ ID NO: 2. Applicants respectfully note that previously canceled Claim 7 was originally included in Group I. As Claim 7 was previously canceled, Applicants have not elected Claim 7 as part of Group I.

Claims 7-17 and 20-36 are canceled.

Claim 37 is new.

Support for Claim 37 is found at the originally filed claims and throughout the specification.

Upon entry of the amendment, Claims 1-6, 18-19, and 37 will be active.

No new matter has been added.

Applicants submit this application is now in condition for examination on the merits and early notification of such action is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

James J. Kelly, Ph.D.
Attorney of Record
Registration No. 41,504

Charles J. Andres, Jr., Ph.D.
Registration No. 57,537

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 06/04)